Loading page
Loading page
Loading substance route
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
3-MMC is described as extremely addictive with a high potential for abuse, reportedly more so than mephedrone. Its short-lived euphoric rush combined with dopaminergic effects produces intense compulsive redosing, with users commonly consuming 0.5-2 grams in multi-hour sessions despite intending smaller doses.
Physical dependence can develop with chronic use. Cravings and withdrawal effects may occur upon sudden cessation, though specific withdrawal symptoms are not well-characterized in the literature.
As of March 2022, 27 fatalities with at least some 3-MMC exposure have been confirmed, though 18 involved multiple drugs (typically opioid-stimulant combinations). Approximately nine monointoxication deaths have been reported. Blood concentrations in fatal cases ranged widely from 249 to 1600 ng/mL. Additionally, 291 non-fatal intoxication cases have been documented, predominantly in Poland and Sweden.
Preliminary evidence suggests chronic high-dose use may carry cardiotoxic risks; acute effects include increased heart rate, elevated blood pressure, abnormal heartbeat, and vasoconstriction that can limit blood flow to organs. Heart valve issues have also been suggested but remain poorly characterized.
Preliminary evidence suggests chronic high-dose use may carry neurotoxic risks; symptoms of serotonin depletion are reported with overuse, manifesting as depression, cognitive fatigue, and motivation suppression during comedown periods.
Rhabdomyolysis has been reported as a serious adverse effect, typically in cases involving hyperthermia and physical exertion.
Delirium and confusion can occur at high doses, particularly when combined with temperature dysregulation, overheating, and inability to rest or rehydrate. Risk of delusions and mania may be elevated when combined with dissociatives.
Seizures are a rare but documented adverse effect, more likely in predisposed individuals or when taking heavy doses while dehydrated, undernourished, overheated, or fatigued.
3-MMC was first encountered in Sweden in 2012, emerging on the online research chemical market shortly after the banning of mephedrone in numerous countries. It was created as a designer drug specifically chosen to mimic and replace the functional and structural features of its recently-controlled…
UN Convention on Psychotropic Substances 1971 (Schedule II, placed March 2023)
Prohibited under the Neue-Psychoaktive-Substanzen-Gesetz (New Psychoactive Substances Act). Possession, production, and sale are illegal.
Banned since October 2015 along with numerous other synthetic compounds. This ban significantly impacted global availability as Chinese chemical companies were primary manufacturers.
Controlled under Anlage I of the Betäubungsmittelgesetz (Narcotics Act, Schedule I) since December 13, 2014. Manufacturing, possession, import, export, purchase, sale, procurement, and dispensing without license are prohibited.
Initially classified as a List II (soft drug) substance effective October 28, 2021. Subsequently reclassified to List I (hard drug) in April 2024, carrying more severe penalties for possession and distribution.
Classified as a narcotic substance under Swedish drug control legislation.
Classified as a controlled drug. Possession, production, supply, and importation are prohibited.
Illegal as a positional isomer of the controlled substance mephedrone. Explicitly designated as a controlled substance on December 13, 2023, and categorized by the DEA as a Schedule I positional isomer.
Listed on Portaria SVS/MS nº 344. Possession, production, and sale are prohibited under this regulation.
Banned substance under national drug control legislation.
Designated as a narcotic substance on February 8, 2024, making possession, production, and distribution illegal.
Classified as a II-P category controlled substance since April 25, 2024, making possession, production, and distribution illegal.
Regulated as a defined derivative of cathinone under Verzeichnis E point 1. Use is permitted for legitimate scientific or industrial purposes only.
Controlled as a Class B substance under the Misuse of Drugs Act 1971 through the cathinone catch-all clause, which covers structurally related compounds.
19 sources cited